Jak Inhibitors for Treatment of Autoimmune Diseases: Lessons from Systemic Sclerosis and Systemic Lupus Erythematosus (original) (raw)
Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
ANCA CARDONEANU
International Journal of Molecular Sciences
View PDFchevron_right
Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent
Antonis Fanouriakis
Cells
View PDFchevron_right
Janus kinase inhibitors in autoimmune diseases
Yoshiya Tanaka
Annals of the Rheumatic Diseases, 2013
View PDFchevron_right
Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection
Paul Changelian
Journal of Medicinal Chemistry, 2010
View PDFchevron_right
Clinical perspectives of Janus Kinase Inhibitors: A review
Sadanand Mallurwar
Asian Journal of Pharmacy and Pharmacology
View PDFchevron_right
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Diseases
Christopher Brummel
Journal of medicinal chemistry, 2015
View PDFchevron_right
Janus Kinase Enzyme (Jak) Inhibitors and Rheumatoid Arthritis: A Review of the Literature
hana morrissey
International Journal of Current Pharmaceutical Research
View PDFchevron_right
Evaluation of JAK3 biology in autoimmune disease using a highly selective, irreversible JAK3 inhibitor
Lauren Dorosh
The Journal of pharmacology and experimental therapeutics, 2017
View PDFchevron_right
JAK Kinases in Health and Disease: An Update
Olli Silvennoinen
2012
View PDFchevron_right
Developments with investigational Janus kinase inhibitors for rheumatoid arthritis
Patrice Decker
Expert Opinion on Investigational Drugs, 2016
View PDFchevron_right
Therapeutic treatment of a novel selective JAK3/JAK1/TBK1 inhibitor, CS12192, in rat and mouse models of rheumatoid arthritis
Lijun Xin
International Immunopharmacology, 2019
View PDFchevron_right
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
Juuli Raivola
BioDrugs
View PDFchevron_right
Suppression of Autoimmune Arthritis by Small Molecule Inhibitors of the JAK/STAT Pathway
C. Malemud
Pharmaceuticals, 2010
View PDFchevron_right
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
Francesco Scaglione
Biomolecules, 2020
View PDFchevron_right
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
Paul Changelian
Current Opinion in Pharmacology, 2012
View PDFchevron_right
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Joel Kremer
Annals of the Rheumatic Diseases, 2020
View PDFchevron_right
A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis
Cynthia Serdikoff
Arthritis Research & Therapy, 2011
View PDFchevron_right
Janus kinases to jakinibs: from basic insights to clinical practice
Olli Silvennoinen
Rheumatology, 2019
View PDFchevron_right
Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice
Martin Hegen, Rustem Krykbaev
Arthritis & Rheumatism, 2010
View PDFchevron_right
Kinase Inhibition — A New Approach to the Treatment of Rheumatoid Arthritis
David Fox
New England Journal of Medicine, 2012
View PDFchevron_right
Therapeutic Targeting of the JAK/STAT Pathway
Saara Aittomaki
Basic & Clinical Pharmacology & Toxicology, 2014
View PDFchevron_right
Dual Targeting of Janus Kinase and Bruton’s Tyrosine Kinase: A New Approach to Control the Pathogenesis of Rheumatoid Arthritis
Munawar Ali Munawar
Pakistan Journal of Zoology, 2020
View PDFchevron_right
Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions
Joerg Wenzel
Frontiers in Immunology
View PDFchevron_right
Janus kinases in immune cell signaling
John O'Shea
Immunological Reviews, 2009
View PDFchevron_right
Therapeutic targeting of Janus kinases
John O'Shea
Immunological Reviews, 2008
View PDFchevron_right
Targeting the Janus Kinase Family in Autoimmune Skin Diseases
Michael Howell
Frontiers in Immunology, 2019
View PDFchevron_right
Defective JAK-STAT Pathway Signaling Contributes to Autoimmune Diseases
Charles Malemud
Current Pharmacology Reports, 2018
View PDFchevron_right
New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway
Paul Changelian
Current Opinion in Rheumatology, 2005
View PDFchevron_right
The specificity of JAK3 kinase inhibitors
Paul Changelian
Blood, 2008
View PDFchevron_right